Shots:
- Health Hope Pharma (HHP) has entered into a global licensing & collaboration agreement with Gilead Sciences to advance encequidar in the field of virology
- As per the deal, Gilead will receive exclusive global virology rights to encequidar, while HHP & Hanmi Pharm will provide drug supply, technical support, project collaboration & receive an upfront payment, development, regulatory & sales milestones, with low single-digit royalties on net sales
- Encequidar in combination with Paclitaxel (PO) will be evaluated in a P-III trial for metastatic breast cancer, with enrolment starting in Q4’25 across the U.S., Hong Kong, & New Zealand; eventual launches are planned across the EU, Asia, & the US
Ref: PRNewsWire | Image: Health Hope Pharma and Gilead Sciences| Press Release
Related News:- Evaxion Licenses EVX-B3 Vaccine Candidate to Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
